Michael S Gordon MD
Genitourinary Oncology, Gynecologic Cancer, Hematologic Oncology, Melanoma
Chief Medical Officer at HonorHealth Research Institute Medical Director, Oncology Clinical Trials at HonorHealth Research Institute
Join to view full profile
10510 N 92nd Street Suite 200Scottsdale, AZ 85258
Phone+1 480-323-1350
Dr. Gordon is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Gordon is an oncology specialist based in Scottsdale, AZ, with subspecialties in genitourinary oncology, gynecologic cancer, hematologic oncology, and melanoma. He completed his residency in internal medicine at the University of Chicago and a fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center. As Chief Medical Officer at HonorHealth Research Institute since 2021, he brings experience in areas such as neuro-oncology and immunotherapy. Dr. Gordon has contributed to several publications in high-impact journals like Nature Medicine and JAMA Oncology, and has led numerous clinical trials focusing on advanced solid tumors. He has earned CMS Meaningful Use Stage certifications for medical oncology from 2013 to 2017.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
University of ChicagoResidency, Internal Medicine, 1985 - 1988
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1985
Sophie Davis School for Biomedical Education at CCNYBS, Biomedical Science, 1979 - 1983
Certifications & Licensure
AZ State Medical License 2000 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification OncoEMR by Flatiron Health, Flatiron Health, Inc., 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases.Benjamin L Schlechter, Marwan G Fakih, Apostolia M Tsimberidou, Andrea J Bullock, Agustin Pimentel
Clinical Cancer Research. 2026-08-28 - A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer.Alexa F Viniotis, Gayle S Jameson, Betsy C Wertheim, Denise J Roe, Keehoon Lee
The Oncologist. 2026-06-06 - Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente, Kristine P Lacuna, Hani M Babiker
Clinical Cancer Research. 2026-05-01
Journal Articles
- Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaBeth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer
- E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain MetastasesMitesh J Borad, Raoul Tibes, Michael S Gordon, Ronald L Korn, Investigational New Drugs
Authored Content
- Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018
Press Mentions
Michael Gordon Shared New Pan-Tumor Data from More Than 400 Patients with Refractory Disease – AgenusOctober 25th, 2025- 10 Posts Not to Miss from ESMOOctober 25th, 2025
- Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025October 17th, 2025
Professional Memberships
- Member
- Member
Industry Relationships
- co-Founder, Caremission
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: